Authors
Latest:
Upper tract urothelial carcinoma: An in-depth review for urologists"On-going innovation will continue to drive UTUC management forward, and with it will come on-going challenges of how to best study a relatively rare disease," write the authors.
Latest:
Tania Solomon, PA-C, highlights APP fellowship in urology“They come out of the fellowship competent and competitive in the field to any urology position that they're interested in,” says Tania Solomon, PA-C, MSc.
Latest:
Study shows HIFU noninferior to prostatectomy for localized prostate cancerTreating patients with localized prostate cancer with high-intensity focused ultrasound led to noninferior salvage treatment-free survival vs radical prostatectomy.
Latest:
Biomarker may predict MIBC status following neoadjuvant chemo"The biomarker is better at predicting presence of disease than absence, and the reason that that's important is that's how we can think about the biomarker aiding in careful clinical assessment of patients," says Elizabeth R. Plimack, MD, MS, FASCO.
Latest:
Conference Convenes Experts in the Field of Nuclear Medicine to Advance Prostate Cancer CareThe conference explored the current and future use of PSMA-PET imaging and PSMA radioligand therapy to improve the clinical care of patients with prostate cancer.
Latest:
How to perform office-based blue light cystoscopyBLC with hexaminolevulinate can be an easily replicable procedure in patients with non–muscle-invasive bladder cancer.
Latest:
Trends in coding audits and what physicians can expectRecent trends in medical audits and what physicians can expect with the CMS changes in 2021 to the documentation of E/M codes.
Latest:
Adoption of New Treatment Modalities to Treat BPHPanelist discusses how urologists can benefit from adopting newer treatment modalities like aqua ablation for BPH, emphasizing its growing popularity, ease of learning, and efficiency in improving patient throughput, while still allowing urologists to leverage their existing skills.
Latest:
Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer"4 years following radiation therapy, there is a 25% lower hazard of bowel disorders and a 46% lower hazard of related procedures [in patients who received a spacer],” says Michael R. Folkert, MD, PhD.
Latest:
Transurethral resection of the bladder tumor: Standard technique and new advancementsImprovement in imaging modalities may help in performance of transurethral resection of the bladder tumor.
Latest:
The potential of HER2 targeting in prostate cancer: A case study with trastuzumab deruxtecan"That pan-tumor approval and this patient case really highlight that in prostate cancer, we should be checking HER2 by immunohistochemistry," says Maneesh R. Jain, MD.
Latest:
Smaller medical practices increasingly targeted for cyber attacksPatient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.
Latest:
Expert shares key cybersecurity fundamentals and best practicesCybersecurity training is vital because it is mandated by HIPAA.
Latest:
Future Directions for the Management of Advanced Prostate CancerBobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.
Latest:
Unmet Needs and Treatment Gaps in Prostate CancerThe panel concludes by addressing unmet needs in prostate cancer management, with a particular focus on improving risk stratification methods.
Latest:
Phase 3 CELLEBRATE trial testing regenerative stem cell-based therapy to improve urinary control for womenThe therapy, known as Autologous Muscle Derived Cells for Urinary Sphincter Repair (iltamiocel), involves a medical procedure in which a participant’s own muscle cells are collected, processed, and then injected into the tissues of the urinary passage.
Latest:
Future Research and Development of Abiraterone Combination TherapiesIn this video, experts share their opinion on the potential for novel combination therapies involving micronized abiraterone, particularly in conjunction with PARP inhibitors like olaparib or niraparib, as evidenced in clinical trials such as PROpel and MAGNITUDE. Additionally, they highlight other potential novel combinations like abiraterone with prednisolone and enzalutamide (STAMPEDE trial), and the integration of abiraterone in treatments involving radiation and androgen deprivation therapy (ADT).
Latest:
Future Directions in PSMA-PET ImagingLooking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
Latest:
Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC“Taken altogether, the study remains positive for PFS, but not for overall survival,” says Laurence Albiges, MD, PhD.
Latest:
Expert urges widespread adoption of next-generation sequencing among physiciansNGS empowers clinicians to take proactive measures to prevent disease, enables more precise diagnosis, and provides better insight on the best treatment option.
Latest:
Managing post-prostatectomy incontinence in patients with comorbidities"Most of these comorbidities, while they do affect the bladder, don't seem to affect the surgeries for stress urinary incontinence," says Jaspreet S. Sandhu, MD.
Latest:
UT Money Matters: Roth IRA conversionsExpert insight on pros, cons and optimal strategies when considering converting a traditional IRA to a Roth IRA.
Latest:
How pre-URS tamsulosin use in pediatric patients may reduce repeat procedures“I would say the take-home message for this study is that prescribing tamsulosin for a week prior to an anticipated surgery that involves flexible ureteroscopy is a very simple practice that certainly is within standard of care within pediatric urology," says Kate H. Kraft, MD, MHPE, FACS, FAAP.
Latest:
Ian Metzler, MD, on the role for telemedicine, digital health tools in stone disease“We have to understand as providers that we're not going to be the one and only conduit for this information anymore, which is a good thing, to be honest," says Ian Metzler, MD, MTM.
Latest:
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape“I think we now have really robust data showing that earlier treatment intensification with combination regimens does lead to improved survival for patients with metastatic hormone-sensitive prostate cancer," says Dr Louise Kostos.
Latest:
How to implement an ERAS pathway in your urology practiceProgram encompasses patient counseling, anesthetic planning, and early mobilization.
Latest:
Kari Bailey, MD, on the evolving priorities of women in urology"Things that were typically used to recruit younger physicians need to change because those aren't their priorities anymore," says Kari Bailey, MD.
Latest:
How to approach immune checkpoint inhibitor therapy in prostate cancerNext-generation sequencing identifies subtypes that may benefit from immune checkpoint inhibitors.
Latest:
Advanced bladder cancer patients could keep their bladder under new treatment regime, clinical trial showsAn approach combining chemotherapy and immunotherapy could help preserve quality of life.
Latest:
Subcutaneous nivolumab approved in EU, Canada for solid tumorsThe approvals are supported by findings from the phase 3 CheckMate-67T trial.
